Achillion Reports Interim Results on ACH-3102

[at noodls] – – Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients – – Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic … more

View todays social media effects on ACHN

View the latest stocks trending across Twitter. Click to view dashboard

See who Achillion is hiring next, click here to view